Cell surface markers are proteins expressed on the outer surface of living cells and tissues that are employed in diagnosing various diseases like cancer, autoimmune disorders, and infectious diseases. Cell surface markers play a crucial role in identifying cell types, stages of cell maturation, and detection of abnormal cells.
The global cell surface markers detection market is estimated to be valued at US$ 5,459.5 million in 2024 and is expected to exhibit a CAGR of 9.1% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the cell surface markers detection market are Grifols SA, Abbott Laboratories, Sysmex Corporation, Agilent Technologies Inc., Nexcelom Bioscience, Thermo Fisher Scientific Inc., Siemens Healthineers, Nihon Kohden Corporation, F. Hoffmann-La Roche Ltd., Bio Rad Laboratories Inc., Becton, Dickinson and Company (BD), Qiagen NV, Diasorin SpA (Luminex Corporation), Danaher Corporation (Beckman Coulter Inc.), and IVD Medical Holding Limited (Immucor Inc.), among others.
The key opportunities in the market include rising prevalence of chronic diseases like cancer and autoimmune disorders along with growing adoption of personalized medicine. Cell surface markers are extensively used in identifying disease subtypes, developing customized treatment plans, and analyzing therapeutic response in personalized medicine.
Globally, cell surface markers detection market is expected to witness significant expansion, especially in Asia Pacific and Latin America. Factors such as increasing healthcare expenditure, large population base susceptible to chronic diseases, and growing need for advanced diagnostic procedures drive the market in emerging countries.
Market drivers
The rising adoption of personalized medicine is a key driver contributing to the high growth of the cell surface markers detection market. Personalized medicine helps deliver customized healthcare with medical decisions, treatments, practices, and/or products tailored to individual patients. Cell surface markers play a critical role in personalized medicine by facilitating tailored disease diagnosis and treatment monitoring. This drives increasing demand for cell surface marker analysis for improved disease management.
PEST Analysis
Political: Government regulations on medical devices and invasive diagnostic techniques determine adoption of cell surface markers detection products. Stringent approval process can delay market entry.
Economic: Changing demographics and rise in chronic diseases are major factors driving demand. However, budget constraints in developing nations can limit spending on advanced diagnostics.
Social: Increasing health awareness and screening programs encourage early detection of diseases. Adoption also depends on social acceptance of new non-invasive diagnostic methods.
Technological: Advancements in imaging, labelling methods and data analysis tools improve detection accuracy. Adoption of automated platforms for high-throughput analysis could increase testing volumes.
The North American region accounts for the largest share of the global cell surface markers detection market in terms of value, followed by Europe. Availability of advanced healthcare infrastructure and high per capita healthcare expenditure in countries like the US and Canada support market growth.
The Asia Pacific region is poised to witness the fastest growth during the forecast period. This can be attributed to improving access to modern healthcare services, rising medical tourism, increasing burden of chronic diseases and growing investment by key players to tap opportunities in emerging nations.
